GZMK and neoplasm: Treatment of recGBM with neoadjuvant PD-1 checkpoint blockade improves survival outcomes by increasing anti-tumor T-cell responses, including GZMK; however, this is curtailed by additional T-cell checkpoints and other immunosuppressive pathways by the myeloid populations [38].